Published Online
on October 29, 2009

A more recent version of this article appeared on December 1, 2009

This Article Full Text (PDF) All Versions of this Article: 40/12/3883    most recent STROKEAHA.109.568576v1 Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Google Scholar Articles by Seet, R. C.-S. Articles by Chen, C. P.L. PubMed PubMed Citation Articles by Seet, R. C.-S. Articles by Chen, C. P.L. Related Collections Antiplatelets

Submitted on September 22, 2009
Accepted on September 30, 2009

Optimizing Antiplatelet Therapy in High-Risk Patients With Atrial Fibrillation. Insights From Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE A)

Raymond Chee-Seong Seet MD^* and Christopher P.L. Chen MD

From the Departments of Medicine (R.C.S.S., C.P.L.C.) and Pharmacology (C.P.L.C.), Yong Loo Lin School of Medicine, National University Singapore; and the Department of Medicine (R.C.S.S.), National University Hospital, Singapore.

^* To whom correspondence should be addressed. E-mail: raymond_seet{at}nus.edu.sg.

Key words: ACTIVE A • aspirin • atrial fibrillation • clopidogrel